Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

P3 Health Partners (PIII) EBITDA: 2019-2024

Historic EBITDA for P3 Health Partners (PIII) over the last 6 years, with FY2024 value amounting to -$318.3 million.

  • P3 Health Partners' EBITDA rose 5890.31% to -$43.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$252.5 million, marking a year-over-year decrease of 340.81%. This contributed to the annual value of -$318.3 million for FY2024, which is 9215.0% down from last year.
  • According to the latest figures from FY2024, P3 Health Partners' EBITDA is -$318.3 million, which was down 9215.0% from -$165.6 million recorded in FY2023.
  • In the past 5 years, P3 Health Partners' EBITDA registered a high of -$28.6 million during FY2020, and its lowest value of -$1.6 billion during FY2022.
  • Its 5-year average for EBITDA is -$439.7 million, with a median of -$165.6 million in 2023.
  • In the last 5 years, P3 Health Partners' EBITDA surged by 8937.26% in 2023 and then plummeted by 9215.0% in 2024.
  • Over the past 5 years, P3 Health Partners' EBITDA (Annual) stood at -$28.6 million in 2020, then tumbled by 346.2% to -$127.6 million in 2021, then crashed by 1121.81% to -$1.6 billion in 2022, then soared by 89.37% to -$165.6 million in 2023, then plummeted by 92.15% to -$318.3 million in 2024.
  • Its EBITDA stands at -$318.3 million for FY2024, versus -$165.6 million for FY2023 and -$1.6 billion for FY2022.